MDA CLINICAL & SCIENTIFIC CONFERENCE

First-Ever Combined Conference Holds Unique Opportunities to Learn and Exchange Ideas Across Disciplines



More than 1,000 clinical and scientific professionals will attend Progress in Motion, the 2019 MDA Clinical & Scientific Conference on April 13–17 in Orlando, Fla.

This conference is a unique opportunity for the scientific, clinical research and clinical practice communities to come together to learn and exchange ideas. The agenda covers critical topics in the neuromuscular disease field, including:

- Care Across the Lifespan
- Clinical Trials
- DNA & RNA Repeat Diseases
- Gene-Targeting Therapies
- Genetics for Healthcare Providers
- Imaging & Biomarkers
- Inflammation, Immune Mechanisms & Therapeutic Approaches
- In Vivo Models & Experimental Therapeutics
- Newborn Screening
- Outcome Measures for Neuromuscular Diseases
- Practical Implementation of New Therapies
- What's New in Neuromuscular Diseases

See the full conference agenda **here**.

Announcing Janet Woodcock as Keynote Speaker

We are pleased to announce that Dr. Janet Woodcock, Director, Center for Drug Evaluation and Research at the Food and Drug Administration, will be joining us as keynote speaker at MDA's upcoming Clinical & Scientific Conference on Monday, April 15, 2019, at 9 a.m. We are honored that Dr. Woodcock will be joining us.

Dr. Woodcock will share her perspectives on the power of data and sharing of information across stakeholder groups, along with other important and timely topics around therapy development.

Hundreds of medical and scientific professionals will be attending Progress in Motion to learn from, be inspired by and share ideas with experts from academic, clinical, government and industrial arenas, and to participate in robust sessions and conversations around the most important areas in neuromuscular disease.

Please **register today** to be part of this exciting conference and to support MDA's mission to transform the lives of individuals living with muscular dystrophy, ALS, and related neuromuscular diseases.